| Revenue growth | 12.3% YoY consolidated FY26; 21.3% YoY Q4 FY26. |
|---|---|
| Margins | Gross margin expanded 130bps in FY26 via product mix optimization. |
| Demand visibility | Strong; cumulative stent deployments surpassed ~11K units. |
| Management confidence | High; citing 21% sequential H1 to H2 growth in-line with guidance. |
Growth
FY26 Consolidated Revenue reached ₹1,875.3 Cr (up 12.3%); Consolidated PAT was ₹320.7 Cr (down 5.3% due to acquisition costs/subsidiary provisions).
Outlook
Guidance for FY27 patient enrollment in clinical trials; capex of ₹296 Cr in FY26; focused on Cardiology/Orthopaedics expansion.
Risks
Q4 EBITDA impacted by one-time regulatory and employee costs in subsidiaries; global supply chain and pricing challenges.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,599.50
- Market cap
- ₹16,213 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 51.5×Sector 53.1×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Annual Report
Poly Medicure has filed its Notice of the 31st Annual General Meeting and the Annual Report for the financial year ended March 31, 2026.
Poly Medicure Dividend
Poly Medicure has announced a record date of August 29, 2026, for a final dividend of ₹3.50 per equity share for FY 2025-26.
Poly Medicure Annual General Meeting
Poly Medicure Limited has scheduled its 31st Annual General Meeting for September 05, 2026, to transact ordinary and special businesses, including dividend declaration.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Employee Stock Options
Poly Medicure Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's paid-up share capital.